Amneal Pharmaceuticals (AMRX) Change in Cash (2017 - 2026)

Amneal Pharmaceuticals' Change in Cash history runs 10 years deep, the most recent figure standing at -$108.5 million for Q1 2026.

• On a quarterly basis, Change in Cash fell 116.95% year-over-year to -$108.5 million in Q1 2026; TTM through Mar 2026 was $136.0 million, a 710.72% increase from a year earlier, with the FY2025 full-year figure at $194.5 million, up 907.19% from the prior year.
• Change in Cash eased to -$108.5 million in Q1 2026 per AMRX's latest filing, from $74.5 million in the prior quarter.
• Across five years, Change in Cash topped out at $154.7 million in Q3 2025 and bottomed at -$118.4 million in Q2 2022.
• The 5-year median for Change in Cash is -$2.3 million (2022), against an average of -$3.1 million.
• Across the five-year window, Change in Cash sank 728.24% in 2023 and soared 1045.0% in 2024, its largest moves.
• Year by year, Change in Cash stood at -$60.7 million in 2022, then jumped by 105.77% to $3.5 million in 2023, then surged by 1045.0% to $40.1 million in 2024, then surged by 85.98% to $74.5 million in 2025, then tumbled by 245.62% to -$108.5 million in 2026.
• Per Business Quant, the three latest AMRX Change in Cash figures stand at -$108.5 million (Q1 2026), $74.5 million (Q4 2025), and $154.7 million (Q3 2025).